Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACLX NASDAQ:ARWR NYSE:HHH NASDAQ:TSHA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACLXArcellx$84.07+0.9%$78.23$47.86▼$107.37$4.62B0.31566,813 shs429,419 shsARWRArrowhead Pharmaceuticals$37.35-0.7%$30.24$9.57▼$40.29$5.20B1.131.93 million shs1.26 million shsHHHHoward Hughes$81.34+0.5%$79.37$61.40▼$87.77$4.81B1.23345,435 shs158,010 shsTSHATaysha Gene Therapies$4.94$3.63$1.05▼$5.51$1.35B0.9911.69 million shs4.18 million shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACLXArcellx+0.85%-5.38%+6.22%+17.89%-4.67%ARWRArrowhead Pharmaceuticals-0.74%-4.16%+14.92%+137.29%+87.50%HHHHoward Hughes+0.62%+2.06%+0.95%+16.58%+5.74%TSHATaysha Gene Therapies0.00%-2.76%+69.18%+86.42%+150.76%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACLXArcellx$84.07+0.9%$78.23$47.86▼$107.37$4.62B0.31566,813 shs429,419 shsARWRArrowhead Pharmaceuticals$37.35-0.7%$30.24$9.57▼$40.29$5.20B1.131.93 million shs1.26 million shsHHHHoward Hughes$81.34+0.5%$79.37$61.40▼$87.77$4.81B1.23345,435 shs158,010 shsTSHATaysha Gene Therapies$4.94$3.63$1.05▼$5.51$1.35B0.9911.69 million shs4.18 million shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACLXArcellx+0.85%-5.38%+6.22%+17.89%-4.67%ARWRArrowhead Pharmaceuticals-0.74%-4.16%+14.92%+137.29%+87.50%HHHHoward Hughes+0.62%+2.06%+0.95%+16.58%+5.74%TSHATaysha Gene Therapies0.00%-2.76%+69.18%+86.42%+150.76%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACLXArcellx 2.86Moderate Buy$113.0834.51% UpsideARWRArrowhead Pharmaceuticals 2.78Moderate Buy$43.1415.51% UpsideHHHHoward Hughes 2.80Moderate Buy$83.332.46% UpsideTSHATaysha Gene Therapies 2.91Moderate Buy$9.6795.68% UpsideCurrent Analyst Ratings BreakdownLatest TSHA, HHH, ARWR, and ACLX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/21/2025TSHATaysha Gene TherapiesRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageStrong-Buy$13.0010/17/2025TSHATaysha Gene TherapiesNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.0010/17/2025TSHATaysha Gene TherapiesChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$12.0010/16/2025ACLXArcellxStifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetBuy$129.0010/9/2025ACLXArcellxCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral$88.0010/9/2025ACLXArcellxCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold$88.0010/8/2025ACLXArcellxWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025ARWRArrowhead PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025ARWRArrowhead PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$80.0010/8/2025HHHHoward HughesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C-)10/8/2025TSHATaysha Gene TherapiesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 10/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACLXArcellx$56.98M81.83N/AN/A$8.41 per share10.00ARWRArrowhead Pharmaceuticals$572.98M9.01N/AN/A$1.54 per share24.25HHHHoward Hughes$1.75B2.76$9.74 per share8.35$56.65 per share1.44TSHATaysha Gene Therapies$8.33M161.78N/AN/A$0.35 per share14.11Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACLXArcellx-$107.35M-$3.42N/AN/AN/A-329.93%-43.04%-27.41%11/6/2025 (Estimated)ARWRArrowhead Pharmaceuticals-$599.49M-$1.28N/AN/AN/AN/A-40.91%-11.62%11/25/2025 (Estimated)HHHHoward Hughes$200.55M$4.5717.8088.41N/A12.85%10.51%3.15%N/ATSHATaysha Gene Therapies-$89.30M-$0.34N/AN/AN/A-1,144.97%-78.44%-44.82%11/12/2025 (Estimated)Latest TSHA, HHH, ARWR, and ACLX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/12/2025Q3 2025TSHATaysha Gene Therapies-$0.09N/AN/AN/A$1.51 millionN/A11/6/2025Q3 2025ACLXArcellx-$1.00N/AN/AN/A$11.24 millionN/A8/12/2025Q2 2025TSHATaysha Gene Therapies-$0.07-$0.09-$0.02-$0.09$1.61 million$1.99 million8/7/2025Q2 2025ACLXArcellx-$1.03-$0.94+$0.09-$0.94$16.76 million$7.55 million8/7/2025Q3 2025ARWRArrowhead Pharmaceuticals-$0.94-$1.26-$0.32-$1.26$29.01 million$27.77 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACLXArcellxN/AN/AN/AN/AN/AARWRArrowhead PharmaceuticalsN/AN/AN/AN/AN/AHHHHoward HughesN/AN/AN/AN/AN/ATSHATaysha Gene TherapiesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACLXArcellxN/A3.813.81ARWRArrowhead Pharmaceuticals0.394.874.87HHHHoward Hughes1.851.181.18TSHATaysha Gene Therapies0.1712.4812.48Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACLXArcellx96.03%ARWRArrowhead Pharmaceuticals62.61%HHHHoward Hughes93.83%TSHATaysha Gene Therapies77.70%Insider OwnershipCompanyInsider OwnershipACLXArcellx8.35%ARWRArrowhead Pharmaceuticals4.30%HHHHoward Hughes48.00%TSHATaysha Gene Therapies3.78%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACLXArcellx8055.46 million50.83 millionOptionableARWRArrowhead Pharmaceuticals400138.26 million132.31 millionOptionableHHHHoward Hughes60859.40 million30.89 millionOptionableTSHATaysha Gene Therapies180272.80 million262.48 millionOptionableTSHA, HHH, ARWR, and ACLX HeadlinesRecent News About These CompaniesRaymond James Initiates Coverage of Taysha Gene Therapies (TSHA) with Strong Buy RecommendationOctober 22 at 4:19 AM | msn.comTaysha Gene Therapies (NASDAQ:TSHA) Trading Up 9.1% - Time to Buy?October 22 at 2:59 AM | marketbeat.comTaysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives Consensus Recommendation of "Moderate Buy" from BrokeragesOctober 22 at 2:49 AM | americanbankingnews.comTaysha Gene Therapies, Inc. (NASDAQ:TSHA) Given Average Rating of "Moderate Buy" by AnalystsOctober 22 at 2:47 AM | marketbeat.comTaysha Gene Therapies (NASDAQ:TSHA) Shares Gap Up - Time to Buy?October 21 at 11:59 AM | marketbeat.comRaymond James Financial Begins Coverage on Taysha Gene Therapies (NASDAQ:TSHA)October 21 at 8:09 AM | marketbeat.comTaysha Gene Therapies initiated with a Strong Buy at Raymond JamesOctober 20, 2025 | msn.comTaysha Gene Therapies' (TSHA) "Buy" Rating Reiterated at Needham & Company LLCOctober 20, 2025 | americanbankingnews.comTaysha Gene Therapies' (TSHA) Buy Rating Reiterated at Chardan CapitalOctober 20, 2025 | americanbankingnews.comTaysha Gene Therapies (NASDAQ:TSHA) Shares Down 11.9% - Here's What HappenedOctober 18, 2025 | marketbeat.comTaysha Gene Therapies (NASDAQ:TSHA) Earns "Buy" Rating from Needham & Company LLCOctober 18, 2025 | marketbeat.comTaysha Gene Therapies (NASDAQ:TSHA) Earns "Buy" Rating from Chardan CapitalOctober 18, 2025 | marketbeat.comHow Regaining Full Rights to Rett Syndrome Gene Therapy Has Changed Taysha (TSHA)’s Investment StoryOctober 17, 2025 | finance.yahoo.comTaysha Gene Therapies, Inc.: Taysha Gene Therapies Regains Full Rights to Lead TSHA-102 Program in Clinical Evaluation for the Treatment of Rett SyndromeOctober 17, 2025 | finanznachrichten.deAstellas walks away from gene therapy pact with Taysha before pivotal trial launchOctober 17, 2025 | fiercebiotech.comFNeedham Reiterates Taysha Gene Therapies (TSHA) Buy RecommendationOctober 17, 2025 | msn.comTaysha Gene Therapies Regains Full Rights to Rett Syndrome ProgramOctober 16, 2025 | marketwatch.comTaysha Gene Therapies regains full rights to TSHA-102 programOctober 16, 2025 | msn.comTaysha Gene Therapies Regains Full Rights to Lead TSHA-102 Program in Clinical Evaluation for the Treatment of Rett SyndromeOctober 16, 2025 | globenewswire.comTaysha Gene Therapies (NASDAQ:TSHA) Hits New 52-Week High - Should You Buy?October 15, 2025 | marketbeat.comTruist Financial Remains a Buy on Taysha Gene Therapies (TSHA)October 12, 2025 | theglobeandmail.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTSHA, HHH, ARWR, and ACLX Company DescriptionsArcellx NASDAQ:ACLX$84.07 +0.71 (+0.85%) Closing price 10/23/2025 04:00 PM EasternExtended Trading$84.02 -0.05 (-0.06%) As of 05:28 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In addition, the company's preclinical product includes ACLX-003 for the treatment of AML and MDS. Further, it focuses on the development of product candidates for solid tumor programs. It has a strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize anitocabtagene autoleucel. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.Arrowhead Pharmaceuticals NASDAQ:ARWR$37.35 -0.28 (-0.74%) Closing price 10/23/2025 04:00 PM EasternExtended Trading$37.53 +0.18 (+0.50%) As of 06:13 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.Howard Hughes NYSE:HHH$81.33 +0.44 (+0.54%) Closing price 10/23/2025 03:59 PM EasternExtended Trading$81.40 +0.07 (+0.08%) As of 10/23/2025 06:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Howard Hughes Holdings Inc., together with its subsidiaries, operates as a real estate development company in the United States. It operates in four segments: Operating Assets; Master Planned Communities (MPCs); Seaport; and Strategic Developments. The Operating Assets segment consists of developed or acquired retail, office, and multi-family properties along with other retail investments. Its MPCs segment develops, sells, and leases residential and commercial land designated for long-term community development projects in and around Las Vegas, Nevada; Houston, Texas; and Phoenix, Arizona. The Seaport segment is involved in the landlord operations, managed businesses, and events and sponsorships services of its restaurant, retail, and entertain properties in Pier 17, New York City; Historic Area/Uplands; and Tin Building, as well as in 250 Water Street and in the Jean-Georges restaurants. The Strategic Development segment develops and redevelops residential condominiums and commercial properties. It serves homebuilders. Howard Hughes Holdings Inc. was founded in 2010 and is headquartered in The Woodlands, Texas.Taysha Gene Therapies NASDAQ:TSHA$4.94 0.00 (0.00%) Closing price 10/23/2025 04:00 PM EasternExtended Trading$5.16 +0.22 (+4.35%) As of 05:05 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Tesla’s Earnings Review: Does the Juice Justify the Squeeze? Warner Bros. Bidding War Potential: How High Could WBD Shares Go? Boeing Takes Off as FAA Greenlights 737 MAX Production Boost Capital One Just Flashed a Buy Signal—New Highs Could Be Next Why Intuitive Surgical Is a No-Brainer for Long-Term Investors Is Oracle’s AI Rally Over? Wall Street Thinks ORCL Could Hit $400 GM Posts Largest Gain Since the Pandemic: Shares Still Look Cheap 3 Pharmaceutical Growth Stocks to Buy and Hold for 10 Years Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
